

FUND DESCRIPTION

Strategy:

The Horizon Kinetics Medical ETF (the "Fund") seeks long-term growth of capital. The Fund is an actively-managed exchange-traded fund ("ETF") that will invest primarily in patented first line pharmaceuticals and biologics as these products tend to have high profit margins and significant barriers to entry. The Fund employs a long-term perspective, seeking to capture returns of both intrinsic valuation realization and scientific discovery.

Portfolio Managers:

Paul Abel – 23 years of experience

FUND DETAILS

Ticker/CUSIP	MEDX / 53656G5633
Inception Date(s)	September 30, 1999, to be converted to ETF on January 27, 2023 ¹
Expense Ratio	0.85%
Index Tracked	None (Active ETF)
Issuer	Foreside
Stock Exchange	NASDAQ
Net Assets	\$19,259,685 (as of 2/2/23)

INVESTMENT CRITERIA

The Fund targets companies that:

- Have high potential return equity
- Are focused on long-term operating results
- Have sufficient cash to pursue drug development
- Allow transparency into their trials and results
- Are either potential buy-out candidates or are actively reviewing the landscape to acquire companies that complement existing business lines

PORTFOLIO CONSTRUCTION

Core Allocation: Biopharma with streamlined operations focusing on the highest margins and best returns on equity, particularly in the development and commercialization of revolutionary therapeutics

Opportunistic: Public Venture Capital at the cutting edge of advances in science

ATTRIBUTES

High profit margins

High barriers to entry

Relatively insensitive to economic turmoil

THE FIRM

- Independent, employee owned, since 1994
- \$8 billion in firm-wide assets under management
- Headquartered in New York with 75 employees
- Co-founders investing together for over 30 years
- Author of independent research since 1995
- 19 Investment Professionals with an average tenure of 19 years with the firm and 29 years in the industry
- No turnover of senior portfolio management since inception of the firm

All data as of December 31, 2022 unless otherwise stated.

¹ Effective at the close of business on 1/27/2023, the Medical Fund will be converted into shares of the Horizon Kinetics Medical ETF as part of a tax-free reorganization. For further details, please refer to: <https://kineticsfunds.com/wp-content/uploads/2022/12/KMF-Shareholder-Notice-Jan-4-2023.pdf>

DISCLOSURES

Please consider carefully a fund's investment objectives, risks, charges and expenses. For this and other important information, obtain a statutory prospectus and summary prospectus by contacting 646-495-7333. Read it carefully before investing.

FUND RISKS:

Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV) and may trade at a discount or premium to NAV. Shares are not individually redeemable from the Fund and may only be acquired or redeemed from the fund in creation units.

Equity Market Risk. The equity securities held in the Fund's portfolio may experience sudden, unpredictable drops in value or long periods of decline in value. **Emerging Markets Risk.** The Fund may invest in companies organized in emerging market nations. Investments in securities and instruments traded in developing or emerging markets, or that provide exposure to such securities or markets, can involve additional risks relating to political, economic, currency fluctuations or regulatory conditions not associated with investments in U.S. securities and instruments or investments in more developed international markets. **Non-Diversification Risk.** The Fund is considered to be non-diversified, which means that it may invest more of its assets in the securities of a single issuer or a smaller number of issuers than if it were a diversified fund. **New Fund Risk.** The Fund is a recently organized investment company with no operating history. As a result, prospective investors have no track record or history on which to base their investment decision.

Associated Risks of Investing in the Medical Industry. Medical and pharmaceutical related companies in general are subject to the rate of change in technology, which is generally higher than that of other industries. **Below Investment Grade Bonds Risk.** The Fund's investments in below investment grade bonds are subject to a greater risk of loss of income and principal than higher grade debt securities. **Concentration Risk.** The Fund expects to concentrate (*i.e.*, invest more than 25% of its net assets) its investments in a limited number of issuers **Derivatives Risk.** Put and call options are referred to as "derivative" instruments since their values are based on, or derived from, an underlying reference asset, such as an index. **Liquidity Risk.** Liquidity risk refers to the possibility that the Fund may not be able to sell or buy a security or close out an investment contract at a favorable price or time. **Non-Diversification Risk.** Because the Fund is "non-diversified," it may invest a greater percentage of its assets in the **Options Risk.** The prices of options may change rapidly over time and do not necessarily move in tandem with the price of the underlying securities.